We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s SKYLINE Study Will Test Gantenerumab in Presymptomatic Patients
Roche’s SKYLINE Study Will Test Gantenerumab in Presymptomatic Patients
Gantenerumab, another anti-amyloid antibody, is entering the race to find an effective therapy for Alzheimer’s disease (AD), with an ambitious four-year study in presymptomatic, amyloid-positive subjects.